Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 113 participants.
Also called NCT03406377
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 113 participants
- Sponsor
- Registry
-
NCT03406377
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03406377. Randomized; triple masking; primary purpose treatment. Start 2018-04-02 (actual); primary completion 2019-03-08 (actual). Results posted on 2021-06-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- OPK-88003
- Intervention (Drug)
- Placebo
- Lead sponsor
- OPKO Health, Inc.
Record details
- Record id
cardio:ct-nct03406377- Content hash
2c215ed59691fb122f5036d6dda17d98fd052c3ce7d6517af9c9b8a17ae8150a